Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Epidemiology: Epilepsy | Mar 2011 | £3,605 | 100% |
| Epilepsy Therapy Area Pipeline Report | Mar 2011 | £945 | 99% |
| Stakeholder Insight: Epilepsy Neurologists remain loyal to brands in genericized market |
Dec 2010 | £9,615 | 97% |
| Epilepsy Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Dec 2011 | £2,215 | 97% |
| Epilepsy - Pipeline Review H2 2011 |
Sep 2011 | £315 | 96% |
| Epilepsy Global Clinical Trials Review H2 2011 |
Oct 2011 | £630 | 96% |
| Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors |
Oct 2006 | £7,210 | 95% |
| Pipeline Insight: Epilepsy Past successes hard to emulate in highly genericized market |
May 2010 | £7,210 | 94% |
| Specialty Pharmaceutical Industry 2011 Yearbook |
May 2011 | £2,215 | 91% |
| Anticonvulsants Market to 2016 Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies |
Jan 2011 | £2,215 | 91% |
| CNS Market Trends, 2007 to 2010 Key Market Forecasts and Growth Opportunities |
Jun 2007 | £995 | 89% |
| Clinical Trial Recruitment in Central Nervous System Disorders Highest Number of Patients Were Recruited for Clinical Trials in Schizophrenia |
Sep 2011 | £2,215 | 89% |
| Analysis of Deals in Neurodegenerative Diseases | Jul 2010 | £2,800 | 89% |
| CNS Therapeutics | May 2008 | £2,500 | 88% |
| Endpoints - Clinical Trials in CNS Disorders Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted |
Nov 2011 | £2,215 | 88% |
| Central Nervous System Disorders Therapeutics Market to 2017 Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half The Market Value in 2010 |
Nov 2011 | £2,215 | 87% |
| World Market for Neurotherapeutic Drugs; The | Sep 2005 | £2,215 | 87% |
| The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis |
Dec 2009 | £2,215 | 85% |
| CNS Generic Drugs: Prospects and Opportunities to 2012 | Apr 2008 | £995 | 82% |
| Advances in Neurostimulators | Apr 2010 | £4,110 | 82% |
| UCB S.A.: PharmaVitae Profile | Dec 2010 | £3,605 | 81% |
| Nanotechnology in Healthcare Market Outlook for Applications, Tools and Materials, and 40 Company Profiles |
Jan 2010 | £2,425 | 80% |
| Pediatric Health Care Products and Services | Mar 2009 | £3,065 | 80% |
| Therapeutic Drugs for Central Nervous System (CNS) Disorders Technologies and Global Markets |
Sep 2010 | £3,065 | 79% |
| Neurostimulation - Advanced Technologies and Global Market 2009 - 2014 |
Sep 2009 | £2,940 | 79% |
| CNS Therapeutics A World Market Review |
Nov 2009 | £1,895 | 78% |
| Stakeholder Opinions: Diagnostics in Neurology Predictive Biomarkers Expand Drug Revenues |
Jul 2008 | £2,400 | 78% |
| Neuromodulation Devices: World Market Prospects 2011-2021 |
Oct 2011 | £1,699 | 77% |
| Neuroprotection (2 parts) Technologies, Markets and Companies |
Jan 2012 | £3,240 | 76% |
| Medtronic, Inc. Product Pipeline Analysis | Jan 2009 | £475 | 75% |
